This mechanism was proposed to contribute to the growth of KRAS, myc-overexpressing NSCLC cancers, suggesting that targeting cholesterol metabolism may be explored as a novel approach for lung cancer treatment with diagnostic and stratification potential [84]. This evidence concerns the gene KRAS and lung cancer.